Back to Search Start Over

Alpha-1 antitrypsin deficiency research and emerging treatment strategies: what's down the road?

Authors :
Rahaghi FF
Source :
Therapeutic advances in chronic disease [Ther Adv Chronic Dis] 2021 Jul 29; Vol. 12_suppl, pp. 20406223211014025. Date of Electronic Publication: 2021 Jul 29 (Print Publication: 2021).
Publication Year :
2021

Abstract

Intravenous infusion of alpha-1 antitrypsin (AAT) was approved by the United States Food and Drug Administration (FDA) to treat emphysema associated with AAT deficiency (AATD) in 1987 and there are now several FDA-approved therapy products on the market, all of which are derived from pooled human plasma. Intravenous AAT therapy has proven clinical efficacy in slowing the decline of lung function associated with AATD progression; however, it is only recommended for individuals with the most severe forms of AATD as there is a lack of evidence that this treatment is effective in treating wild-type heterozygotes (e.g., PI*MS and PI*MZ genotypes), for which the prevalence may be much higher than previously thought. There are large numbers of individuals that are currently left untreated despite displaying symptoms of AATD. Furthermore, not all countries offer AAT augmentation therapy due to its expense and inconvenience for patients. More cost-effective treatments are now being sought that show efficacy for less severe forms of AATD and many new therapeutic technologies are being investigated, such as gene repair and other interference strategies, as well as the use of chemical chaperones. New sources of AAT are also being investigated to ensure there are enough supplies to meet future demand, and new methods of assessing response to treatment are being evaluated. There is currently extensive research into AATD and its treatment, and this chapter aims to highlight important emerging treatment strategies that aim to improve the lives of patients with AATD.<br />Competing Interests: Conflict of interest statement: FFR is a consultant, speaker, and researcher for Takeda and Grifols, and a consultant for CSL Behring.<br /> (© The Author(s), 2021.)

Details

Language :
English
ISSN :
2040-6223
Volume :
12_suppl
Database :
MEDLINE
Journal :
Therapeutic advances in chronic disease
Publication Type :
Academic Journal
Accession number :
34408832
Full Text :
https://doi.org/10.1177/20406223211014025